CA-TREASURE-DATA
Treasure Data ™ today unveiled its Global Partner Program , offering agencies, consultancies, technology service providers, independent software vendors (ISVs) and data specialists new certifications, training, and technical, marketing and sales support for the Company’s market-leading Customer Data Platform (CDP). The program will be launching with 20 strategically selected partners and is set to grow as we continue to expand our customer base in all territories.
“Enterprises are turning to trusted partners in their respective industries to accelerate customer-centric digital transformation and solve complex data, scale and other obstacles that hinder exceptional brand experiences,” said Stephen Lee, Vice President of Strategy and Business Development, Treasure Data. “Treasure Data’s Global Partner Program helps trusted enterprise partners expand their CDP technical acumen and experience to grow their market and revenue opportunities.”
Certified Partners help customers throughout their entire CDP deployment journey. For agencies, and consultancies, the program offers three tiers—bronze, silver and gold—with level-specific commitments for online training, joint marketing, market development funds (MDF), discounts, and technical and sales support. In addition to access to Treasure Data’s CDP Academy training, partners may also receive additional certified sales and technical training matched to key roles ranging from sales and marketing operations to data architects and scientists. The program is also open to select Treasure Data technology partners.
“Acxiom and its partners strive to drive transformational change for clients through strategic partnerships and we’re excited to be working with such a powerful tool as the Treasure Data CDP,” says Mike Menzer, President, Acxiom International. “Customer Data Platforms are creating a lot of growth right now and we see the Acxiom and Treasure Data combination as a key solution to driving value for our clients.”
“CDPs like Treasure Data are playing an increasingly important role in helping marketers better understand who their customers are,” says Jayne Babine, Executive Vice President, Partnerships and Sales at MightyHive. “As one of the leading full-service global marketing services firms, MightyHive is thrilled to be partnering with Treasure Data to make our clients more successful around data marketing strategy and execution.”
Treasure Data’s CDP unifies and unlocks the full potential of customer data. It captures all online and offline customer interactions as they happen, helping companies to understand all brand interactions with the precise detail needed to engage customers at the right time in the right place. Trusted by more than 400 organizations worldwide, Treasure Data provides an enterprise-scale, independent solution that lets partners work with any existing technology stack and gives them the flexibility to ingest all types of data. This makes it easy to integrate the Treasure Data CDP with partner offerings and preferred solutions stacks to accelerate the delivery of outstanding, personalized data-driven brand experiences.
Partners included in Treasure Data’s Global Partner Program: Accenture, Acxiom, MightyHive in the Gold Tier. Allant, BitBang, Brain+Trust Partners, Merkle (Isobar, Sokrati) Search Discovery, SilverBullet in the Silver Tier. AdGlobal360, Ansira, Exostatic, Gravitai, Green Lyzard, HGS Digital, Hero Digital, Hexagon Data, Keyrus, Verticurl in the Bronze Tier. For more information on our partner program, please visit https://www.treasuredata.com/partnerships/
About Treasure Data
Treasure Data Customer Data Platform (CDP) empowers enterprises by delivering rich insights that drive outstanding customer experiences. Built on a strong data management foundation, our CDP enables brands to securely unify customer data across silos at scale so they can better identify, engage and acquire customers. The highly configurable platform boasts a comprehensive connector network that evolves with your existing technology stack to future-proof all customer data initiatives. Treasure Data has more than 400 customers including Fortune 500 and Global 2000 enterprises, and is a wholly-owned subsidiary of Arm Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom